FDA

The Readout LOUD Adam Feuerstein and Allison DeAngelis

STAT Plus: Listen: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)

Biotech Sarah Owermohle, Allison DeAngelis, and Adam Feuerstein

STAT Plus: Biopharma execs cheer Supreme Court for upholding FDA authority in abortion pill case

Politics Sarah Owermohle

STAT Plus: Supreme Court unanimously rejects challenge to mailed abortion pills

The Readout Meghana Keshavan

With Avidity and Pfizer, gene therapy enters a phase

Politics Nicholas Florko

STAT Plus: Senators slam the FDA’s new vape enforcement plan: ‘What in the hell have you been waiting for?’

D.C. Diagnosis Sarah Owermohle

FDA says it’s getting serious about illegal vapes. It’s still likely to get a tongue lashing.

The Readout Meghana Keshavan

The biotech news you missed from the weekend

Health Helen Branswell

STAT Plus: FDA expands approval for GSK’s RSV vaccine to cover younger at-risk adults

The Readout Meghana Keshavan

STAT Plus: Vanda Pharmaceuticals has another suitor

The Readout LOUD Allison DeAngelis and Adam Feuerstein

Listen: Psychedelics at the FDA, ASCO recap, & MorphoSys update

The Readout Elaine Chen

Novavax will be able to supply Covid-19 vaccines this fall

The Readout Jason Mast

STAT Plus: Testing begins for a new form of PrEP

The Readout Meghana Keshavan

STAT Plus: Can AstraZeneca make good on its promise?

Biotech Elaine Chen

STAT Plus: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone

Health Olivia Goldhill

What to watch for in the crucial FDA meeting on MDMA therapy for PTSD

Biotech Helen Branswell

STAT Plus: FDA approves Moderna’s RSV vaccine, its second licensed product

The Readout Meghana Keshavan

STAT Plus: The surprising outperformance of a new drug against existing competitors, and other biotech updates

Health Lev Facher

Drug treatment that insists on abstinence? Federal agencies are just saying no

The Readout Elaine Chen

STAT Plus: Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week

In the Lab Nicholas Florko and Sarah Owermohle

What the rescheduling of marijuana might — and might not — mean for scientific research

Politics Lizzy Lawrence

STAT Plus: Clinical lab trade group sues FDA over plan to regulate lab-developed tests

The Readout Elaine Chen

STAT Plus: Wegovy linked to lower risk of alcohol use disorder in real-world study

The Readout Meghana Keshavan

STAT Plus: Biotech’s most interesting fundraisings from the last week

The Readout Meghana Keshavan

STAT Plus: More tumult at BIO amid the company’s fourth CEO in four years

Pharma Olivia Goldhill

STAT Plus: After MDMA therapy, she considered suicide. The trial data tell a different story

D.C. Diagnosis Rachel Cohrs Zhang

STAT Plus: Pharma’s losing bet in New Jersey

The Readout Elaine Chen

STAT Plus: Maryland takes first steps to cap drug costs

The Readout Elaine Chen

STAT Plus: Blackstone wants in on red-hot immunology market

The Readout Elaine Chen

STAT Plus: Leqembi gets closer to being offered as an injection